

10. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. *Heart*. 2004;90(8):859-65.
11. Ajeganova S, Svensson B, Häfström I et al. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. *BMJ Open*. 2014;4(4):e004259.
12. Pujades-Rodriguez M, Morgan AW, Cubbon RM et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. *PLoS Med*. 2020;17(12):e1003432.
13. Aviña-Zubieta JA, Abrahamowicz M, De Vera MA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. *Rheumatology (Oxford)*. 2013;52(1):68-75.
14. So H, Lam TO, Meng H et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. *Ann Rheum Dis*. 2023;82(11):1387-93.
15. van der Hooft CS, Heeringa J, Brusselle GG et al. Corticosteroids and the risk of atrial fibrillation. *Arch Intern Med*. 2006;166(9):1016-20.
16. Christiansen CF, Christensen S, Mehnert F et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. *Arch Intern Med*. 2009;169(18):1677-83.
17. Akikusa JD, Feldman BM, Gross GJ et al. Sinus bradycardia after intravenous pulse methylprednisolone. *Pediatrics*. 2007;119(3):e778-82.
18. White KP, Driscoll MS, Rothe MJ et al. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? *J Am Acad Dermatol*. 1994;30(5 Pt 1):768-73.
19. Majoor CJ, Kamphuisen PW, Zwinderman AH et al. Risk of deep vein thrombosis and pulmonary embolism in asthma. *Eur Respir J*. 2013;42(3):655-61.
20. Waljee AK, Rogers MA, Lin P et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. *BMJ*. 2017;357:j1415.
21. Lieber BA, Han J, Appelboom G et al. Association of Steroid Use with Deep Venous Thrombosis and Pulmonary Embolism in Neurosurgical Patients: A National Database Analysis. *World Neurosurg*. 2016;89:126-32.
22. Petri M, Perez-Gutthann S, Spence D et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. *Am J Med*. 1992;93(5):513-9.
23. Drosos GC, Vedder D, Houben E et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. *Ann Rheum Dis*. 2022;81(6):768-79.
24. Kršek M. [Systemic glucocorticoids treatment: practical view]. *Vnitř Lek*. 2015;61(10):905-13.



2. kongres diabetologie pro praxi

12. 2. 2025
PARKHOTEL
PLZEŇ

ODBORNÝ GARANT

- MUDr. Michal Krčma, Ph.D.

PLÁNOVANÉ TEMATICKÉ BLOKY

- **DIABETES MELLITUS A TĚHOTENSTVÍ**
Garanti: MUDr. Daniela Čechurová,
as. MUDr. Vladimír Korečko
- **DIABETES MELLITUS A CHIRURGIE**
Garanti: prof. MUDr. Jiří Moláček, Ph.D.,
MUDr. Viktor Zlocha
- **DIABETES MELLITUS
A POSUDKOVÁ ČINNOST**
Garanti: MUDr. Bc. Petra Sládková, Ph.D.,
MUDr. Jan Brož, Ph.D.
- **KAZUISTIKY Z PRAXE**

REGISTRAČNÍ POPLATEK

- při registraci do 31. 12. 2024: **700 Kč**
- při registraci do 6. 2. 2025: **900 Kč**
- při registraci od 7. 2. 2025: **1 100 Kč**
- **40% sleva** pro lékaře do 35 let
- **20% sleva pro předplatitele časopisů
vydavatelství Solen na rok 2025**



www.visitplzen.eu

MÍSTO KONÁNÍ

- Parkhotel Congress Center Plzeň
- U Borského parku 31, Plzeň

POŘADATEL A KONTAKT

- SOLEN, s. r. o.,
v odborné spolupráci
s I. interní klinikou FN Plzeň
- Markéta Slezáková
slezakova@solen.cz
+420 721 135 146